Patents by Inventor BYRON DELABARRE

BYRON DELABARRE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bi-specific fusion proteins for tissue repair
    Patent number: 8691771
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: April 8, 2014
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
  • Bi-specific fusion proteins
    Publication number: 20110293579
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
    Type: Application
    Filed: May 20, 2011
    Publication date: December 1, 2011
    Applicant: Merrimack Pharmaceuticals, Inc.
    Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun Lippow
  • BI-SPECIFIC FUSION PROTEINS
    Publication number: 20110286976
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.
    Type: Application
    Filed: May 20, 2011
    Publication date: November 24, 2011
    Applicant: MERRIMACK PHARMACEUTICALS
    Inventors: ULRIK NIELSEN, THOMAS WICKHAM, BIRGIT SCHOEBERL, BRIAN HARMS, BRYAN LINGGI, MATTHEW ONSUM, BYRON DELABARRE